BCIQ Profiles

Company Profile Report

Genentech adds to autoimmune pipeline with Parvus deal

In its second deal based on its immunomodulatory platform, Parvus granted Genentech rights to develop and commercialize its Navacim nanoparticle therapeutics to treat inflammatory bowel disease (IBD), autoimmune liver

Read the full 294 word article

How to gain access

Continue reading with a
two-week free trial.